| Study group | Number of patients | Intervention (capsule) | Duration | Outcomes | Reference |
| Subjects with T2DM | 37 | 200 mg/day CoQ10 | 12 weeks | ↓HbA1c | [43] | ↓SBP, DBP |
| Subjects with T2DM | 56 | 200 mg/day CoQ10 | 12 weeks | ↓HbA1c | [44] | ↓Weight, BMI |
| Subjects with T2DM with LVDD | 36 | 200 mg/day CoQ10 | 25 weeks | ↓BP | [45] | ↓TG |
| Subjects with CAD | 51 | 300 mg/day CoQ10 | 12 weeks | ↑CAT, SOD, GPx | [46] | ↓TNF-α, IL-6 |
| Subjects with T2DM | 38 | 150 mg/day CoQ10 | 8 weeks | ↓FBG, HbA1c | [47] | ↓TC, LDL, LPa |
| Subjects with hyperlipidemia and MI | 52 | 200 mg/day CoQ10 | 12 weeks | ↑HDL | [48] | ↓TC, LDL | ↓LDL/HDL, TC/HDL | ↓SBP, DBP |
| Subjects with diabetic neuropathy | 62 | 200 mg/day CoQ10 | 12 weeks | ↓HOMA-IR, CRP | [49] | ↑Insulin sensitivity, TAC |
| Subjects with T2DM | 64 | 200 mg/day CoQ10 | 12 weeks | ↓HbA1c | [50] | ↓LDL | ↓ADMA, nitrite and nitrate |
| Subjects with T2DM | 52 | 100 mg/day CoQ10 | 8 weeks | ↓MDA levels | [51] |
| Obese and T2DM subjects with CHD | 60 | 100 mg/day CoQ10 | 8 weeks | ↓HOMO-IR, MDA | [52] | ↑TAC, GSH |
| T2DM subjects with CHD | 60 | 100 mg/day CoQ10 | 8 weeks | ↓IL-6 and protein carbonyl levels | [53] |
| Subjects with T2DM | 68 | 100 mg/day CoQ10 | 12 weeks | ↓FBG | [54] | ↑CoQ10, CAT activity, TAC, and QUICKI |
| Subjects with diabetic nephropathy | 50 | 100 mg/day CoQ10 | 12 weeks | ↓MDA and AGEs levels | [55] | ↑QUICKI |
| Prediabetes subjects | 80 | 200 mg/day CoQ10 | 8 weeks | ↓HOMA-IR and oxygen-free radical | [56] |
| Subjects with T2DM | 50 | 100 mg/day CoQ10 | 12 weeks | ↓HbA1c, MES | [57] | ↑HDL | ↑CAT, GPx |
| Subjects with T2DM | 27 | 100 mg/day CoQ10 | 12 weeks | ↓HbA1c | [58] | ↓oxLDL |
|
|
AGEs, advanced glycation end products; ADMA, asymmetric dimethylarginine; BMI, body mass index; CRP, C-reactive protein; CHD, coronary heart disease; CAD, coronary artery disease; FMD, flow-mediated dilation; GSH, glutathione; HOMO-IR, homeostatic model assessment of insulin resistance; IL-6, interleukin 6; LPO, lipid peroxidation; LPa, lipoprotein(a); MES, medication effect score; QUICKI, quantitative insulin sensitivity check index.
|